August 6, 2022

Third Pole Therapeutics Closes $25 Million Funding

WALTHAM, Mass., February 3, 2022 /PRNewswire/ — Third Pole Therapeutics, a privately held company developing life-sustaining cardiopulmonary therapies, today announced that it has reached several important milestones, including closing a $25 million round of financing, and that eNOfit™, the Company’s fully miniaturized wearable device, is ready for clinical trials.

CEO Bill Athenson said, “We would like to thank our existing investors who continue to support Third Pole’s mission to develop our new technology into approved products for patients in need. We also welcome our new investors who have joined us in supporting this important mission. Mr. Athenson continued: “We are now much closer to improving the lives of 1.2M patients with severe COPD and IPD (pulmonary fibrosis) who struggle with every breath to perform daily activities that most people take for granted. Physician feedback on our new device has been overwhelmingly positive. They tell us that our lightweight mobile device has the potential to reduce high-flow patients’ reliance on supplemental oxygen, improve their mobility by enabling treatment while traveling and at home, and reduce the risk of heart failure by reducing pulmonary hypertension. These benefits may allow patients to live better quality lives, require less intensive hospital care, and live longer.”

The Company anticipates the final eNOfitMT mobile device testing is due to be completed in the first half of this year, with clinical trials beginning later this year and a potential submission to the FDA for clearance by the end of 2023.

The Company is also nearing completion of its eNOcare™ platform, which is expected to enter the current $600 million the hospital nitric oxide market using the same new proprietary NO production technology. Based on eNOcare universal mentionsMT received from cardiopulmonary critical care centers around the world, Third Pole expects rapid adoption and significant market expansion soon after its launch, given its superior safety, user-friendliness and reliability features by compared to other alternative products.

About Third Pole Therapeutics, Inc.
Third Pole Therapeutics develops and delivers life-sustaining cardiopulmonary therapies. Warren Zapol, MD, founder of Third Pole, invented the first use of inhaled nitric oxide (iNO) for the treatment of hypoxic respiratory failure in newborns (blue babies). Since then, in addition to blue babies, hundreds of thousands of pediatric and adult patients suffering from elevated lung pressure, inflammation, and poor oxygenation during and after heart surgery have been treated with oxide. inhaled nitric acid, creating a $600 million inhaled nitric oxide industry, concentrated in major hospitals and developed markets.

Two decades later, Third Pole has succeeded in creating a scalable technology that provides nitric oxide for inhalation, instantly, on demand and in unlimited quantities. Third Pole’s technology solves the cost and logistical issues that have prevented the widespread use of iNO in various markets in the United States and abroad that lacked the training and infrastructure to transport, service, return and refill large compressed gas cylinders safely. Third Pole’s two new platforms include eNOfit™, a miniaturized wearable device for home and travel, and eNOcare™, a lightweight wearable device in the hospital. Both make iNO by combining electricity and the air we breathe, creating “do it and take it” therapy, without the dangers of compressed gas storage. These versatile and extensively patented platforms have the potential to rapidly capture the entire existing reservoir market and expand beyond current indications to treat interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD ), cystic fibrosis and viral and life-threatening diseases. bacterial infections. For more information, visit

Third Pole Therapeutics, Inc.
Elizabeth HolmbergFinancial director
[email protected]
Tiberend Strategic Advisors, Inc.

Investor Relations
Lisa Sher
[email protected]

Media Relations
Dave Schemelia / Rosalyn Christian
[email protected] / [email protected]

SOURCE Third Therapeutic Pole